Lisata Therapeutics Makes Strides in Pancreatic Cancer Trial
TL;DR
Lisata Therapeutics CEO highlights completion of patient enrollment for pancreatic cancer trial, positioning the company ahead in the race for effective cancer treatments.
The CENDIFOX trial led by Dr. Anup Kasi at The University of Kansas Cancer Center is evaluating the safety and efficacy of certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Lisata's Phase 1b/2a CENDIFOX trial aims to collect pre- and post-treatment biopsies of tumors, contributing to the advancement of cancer treatment and bringing hope to patients and their families.
CEO David Mazzo expresses optimism and notes encouraging progress in the trial, drawing attention to the ongoing efforts and anticipated preliminary results by the end of the year.
Found this article helpful?
Share it with your network and spread the knowledge!
Lisata Therapeutics Inc. CEO David Mazzo provided an encouraging update on the company's Phase 1b/2a CENDIFOX trial, a clinical study evaluating the safety and efficacy of certepetide (formerly LSTA1) in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Mazzo announced that Lisata has successfully completed patient enrollment for the pancreatic cancer cohorts in the trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center. This milestone marks a significant step forward in the investigation of certepetide's potential as a treatment option for these challenging cancers.
Notably, the trial design allows for the collection of pre- and post-treatment biopsies of tumors, enabling researchers to gather valuable data on the drug's effects. Mazzo also highlighted ongoing efforts to complete enrollment in two additional cohorts focusing on colorectal cancer and other tumor types, with the goal of completing these cohorts by the end of the year.
Expressing his optimism, Mazzo noted the encouraging progress and enthusiasm surrounding the trial, which has attracted patients from the Kansas City area despite competition from other studies. He anticipates that preliminary results will be available by the end of the year, pending the timely processing of biopsies by external laboratories.
The CENDIFOX trial represents a significant step forward in the search for effective treatments for pancreatic and other challenging cancers. The completion of patient enrollment for the pancreatic cancer cohorts and the potential for preliminary results by year-end underscore the importance of this research and the promising progress being made by Lisata Therapeutics.
Curated from News Direct
